327 épisodes
The Uromigos The Uromigos
-
- Forme et santé
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre
Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
-
Episode 329: Japan in the Uromigos Cup qualifying round
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
-
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
-
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
-
Episode 326 ASCO24: KIM-1 in Renal Cancer
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
-
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
-
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.